Yoshiro Fushimi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yoshiro Fushimi has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Masashi Shimoda
Department of Diabetes, Endocrinology and Metabolism Kawasaki Medical School Kurashiki Japan
21 shared publications - Hideaki Kaneto
Department of Diabetes, Endocrinology and Metabolism Kawasaki Medical School Kurashiki Japan
20 shared publications - Kohei Kaku
Department of Diabetes, Endocrinology and Metabolism Kawasaki Medical School Kurashiki Japan
19 shared publications - Shuhei Nakanishi
Department of Diabetes, Endocrinology and Metabolism Kawasaki Medical School Kurashiki Japan
17 shared publications - Tomohiko Kimura
Department of Diabetes, Endocrinology and Metabolism Kawasaki Medical School Kurashiki Japan
16 shared publications Junpei Sanada
Department of Diabetes, Endocrinology and Metabolism Kawasaki Medical School Kurashiki Japan
13 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Wiley in Journal of Diabetes Investigation
Development and external validation of machine learning models for predicting glucose trajectories after continuous intravenous insulin therapy in hyperglycemic crises
Background and aims: Predicting short‐term blood glucose changes after initiation of continuous intravenous insulin infusion (CII) in hyperglycemic crises remains challenging because glucose trajectories are influenced by both patient‐specific metabolic severity and dynamically adjusted treatment. This study aimed to develop and externally validate machine learning models for estimating retest glucose levels and glucose‐lowering responses after CII initiation. Methods: We analyzed 574 post‐CII blood glucose measurements from 191 patients with hyperglycemic crises across five Japanese institutions. An independent external validation cohort included 29 patients from another institution. Two complementary models were developed using gradient‐boosted decision tree algorithms: a direct retest glucose prediction model and a ΔGlu treatment‐response model. We evaluated model performance using internal validation, patient‐level fivefold cross‐validation, and external validation. ΔGlu was defined as the decrease in blood glucose between two consecutive reassessment points. Results: The eight‐feature direct retest glucose model showed stable predictive performance in internal validation (R 2 = 0.853, MAE = 76.9 mg/dL, RMSE = 106.0 mg/dL), patient‐level fivefold cross‐validation (R 2 = 0.803 ± 0.080), and external validation (R 2 = 0.802, MAE = 78.0 mg/dL, RMSE = 101.0 mg/dL). Although the eight‐feature ΔGlu treatment‐response model showed moderate internal performance, its external generalizability for ΔGlu prediction was limited. Conclusions: The direct retest glucose model showed stable performance across internal and external validation, whereas ΔGlu itself was more difficult to generalize across institutions. These complementary models may support objective monitoring of short‐term glucose trajectories during CII for hyperglycemic crises, although further prospective validation is warranted.
- 11 November 2026
- Published by Wiley in Journal of Diabetes Investigation
Open AccessDevelopment and external validation of machine learning models for predicting glucose trajectories after continuous intravenous insulin therapy in hyperglycemic crises
Background and aims: Predicting short‐term blood glucose changes after initiation of continuous intravenous insulin infusion (CII) in hyperglycemic crises remains challenging because glucose trajectories are influenced by both patient‐specific metabolic severity and dynamically adjusted treatment. This study aimed to develop and externally validate machine learning models for estimating retest glucose levels and glucose‐lowering responses after CII initiation. Methods: We analyzed 574 post‐CII blood glucose measurements from 191 patients with hyperglycemic crises across five Japanese institutions. An independent external validation cohort included 29 patients from another institution. Two complementary models were developed using gradient‐boosted decision tree algorithms: a direct retest glucose prediction model and a ΔGlu treatment‐response model. We evaluated model performance using internal validation, patient‐level fivefold cross‐validation, and external validation. ΔGlu was defined as the decrease in blood glucose between two consecutive reassessment points. Results: The eight‐feature direct retest glucose model showed stable predictive performance in internal validation (R 2 = 0.853, MAE = 76.9 mg/dL, RMSE = 106.0 mg/dL), patient‐level fivefold cross‐validation (R 2 = 0.803 ± 0.080), and external validation (R 2 = 0.802, MAE = 78.0 mg/dL, RMSE = 101.0 mg/dL). Although the eight‐feature ΔGlu treatment‐response model showed moderate internal performance, its external generalizability for ΔGlu prediction was limited. Conclusions: The direct retest glucose model showed stable performance across internal and external validation, whereas ΔGlu itself was more difficult to generalize across institutions. These complementary models may support objective monitoring of short‐term glucose trajectories during CII for hyperglycemic crises, although further prospective validation is warranted.
- Open Access
- 30 August 2026
- Published by Springer Nature in Scientific Reports
Glucocorticoids directly inhibit insulin biosynthesis via the glucocorticoid receptor in pancreatic β-cells
- 30 August 2026
- Published by Springer Nature in Scientific Reports
Open AccessGlucocorticoids directly inhibit insulin biosynthesis via the glucocorticoid receptor in pancreatic β-cells
- 9 February 2026
- Published by Springer Nature in Acta Diabetologica
- Vol. 63 (4) , 701-709
Effect of metformin dose reduction versus continuation at imeglimin initiation on glycemic control in type 2 diabetes: a retrospective real-world analysis
Aims To evaluate whether continuing versus reducing metformin at imeglimin initiation is associated with 24-week changes in HbA1c and body weight in routine practice, and to describe 48-week outcomes. Methods Single-center retrospective study of adults with type 2 diabetes who started imeglimin 2000 mg/day (September 2022–August 2024). For the primary 24-week efficacy analysis, metformin users who tolerated and continued imeglimin through week 24 were classified as metformin continuation (no change) or metformin reduction (≥ 250 mg/day decrease, including discontinuation). The primary endpoint was 24-week ΔHbA1c. Associations were assessed with nonparametric tests and ANCOVA adjusting for age, sex, diabetes duration, and baseline HbA1c; sensitivity models additionally adjusted for baseline metformin dose and major concomitant glucose-lowering drug classes (SGLT2i, GLP-1RA, insulin, and sulfonylureas). Results Seventy metformin users were included (continuation n = 34; reduction n = 36). At 24 weeks, HbA1c decreased by − 0.6% versus − 0.2% (median difference − 0.5%, 95% CI − 0.6 to − 0.3), and body weight by − 1.2 kg versus − 0.4 kg (median difference − 0.9 kg). The absolute metformin dose reduction correlated with ΔHbA1c (Spearman ρ = 0.52). Metformin continuation remained associated with greater adjusted HbA1c reduction in sensitivity ANCOVA (adjusted difference − 0.57%, 95% CI − 0.88 to − 0.26; P = 0.0006). In a 48-week cohort (n = 65) continuing imeglimin, metformin dose reduction remained associated with ΔHbA1c in multivariable analysis. Conclusions Continuing metformin at imeglimin initiation was associated with greater improvements in HbA1c and body weight than dose reduction. Findings are associative and may reflect residual confounding.
- 9 February 2026
- Published by Springer Nature in Acta Diabetologica
- Vol. 63 (4) , 701-709
Effect of metformin dose reduction versus continuation at imeglimin initiation on glycemic control in type 2 diabetes: a retrospective real-world analysis
Aims To evaluate whether continuing versus reducing metformin at imeglimin initiation is associated with 24-week changes in HbA1c and body weight in routine practice, and to describe 48-week outcomes. Methods Single-center retrospective study of adults with type 2 diabetes who started imeglimin 2000 mg/day (September 2022–August 2024). For the primary 24-week efficacy analysis, metformin users who tolerated and continued imeglimin through week 24 were classified as metformin continuation (no change) or metformin reduction (≥ 250 mg/day decrease, including discontinuation). The primary endpoint was 24-week ΔHbA1c. Associations were assessed with nonparametric tests and ANCOVA adjusting for age, sex, diabetes duration, and baseline HbA1c; sensitivity models additionally adjusted for baseline metformin dose and major concomitant glucose-lowering drug classes (SGLT2i, GLP-1RA, insulin, and sulfonylureas). Results Seventy metformin users were included (continuation n = 34; reduction n = 36). At 24 weeks, HbA1c decreased by − 0.6% versus − 0.2% (median difference − 0.5%, 95% CI − 0.6 to − 0.3), and body weight by − 1.2 kg versus − 0.4 kg (median difference − 0.9 kg). The absolute metformin dose reduction correlated with ΔHbA1c (Spearman ρ = 0.52). Metformin continuation remained associated with greater adjusted HbA1c reduction in sensitivity ANCOVA (adjusted difference − 0.57%, 95% CI − 0.88 to − 0.26; P = 0.0006). In a 48-week cohort (n = 65) continuing imeglimin, metformin dose reduction remained associated with ΔHbA1c in multivariable analysis. Conclusions Continuing metformin at imeglimin initiation was associated with greater improvements in HbA1c and body weight than dose reduction. Findings are associative and may reflect residual confounding.
- Open Access
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- p. EJ26-0238
Association of phase angle versus skeletal muscle mass profiling with body fat mass in relation to glycemic control in type 2 diabetes: a cross-sectional study
While preserving skeletal muscle mass (SMM) is advocated in type 2 diabetes mellitus (T2DM), mass-based assessments often overlook muscle quality. This study aimed to investigate whether the balance between cellular integrity (phase angle [PhA]) and metabolic load (body fat mass [BFM]) is more clinically relevant to glycemic control than SMM-based profiling in patients with T2DM. In this cross-sectional study of 622 patients, participants were stratified into four groups based on sex-specific medians of PhA and BFM, and similarly for SMM and BFM. Multivariate logistic regression evaluated associations with glycemic targets (HbA1c <8.0% and <7.0%), adjusting for confounders. Sensitivity analyses utilized continuous Z-scores and interaction terms. High-PhA/High-BFM and High-PhA/Low-BFM groups showed significantly higher odds of HbA1c <8.0% compared with the Low-PhA/High-BFM reference group (adjusted odds ratio [OR] 2.05, 95% confidence interval [CI] 1.22–3.44; OR 2.10, 95% CI 1.21–3.64, respectively). Conversely, SMM/BFM combinations showed no significant associations. Neither profile was significantly associated with the stricter HbA1c <7.0% target. In continuous models, the PhA × BFM interaction was significantly associated with achievement of HbA1c <8.0% (p = 0.025), whereas SMM × BFM interaction was not. In conclusion, the PhA/BFM interplay shows a clearer association with glycemic control than SMM/BFM profiling in T2DM. Higher PhA may reflect a more favorable metabolic phenotype against adiposity and is associated with a lower likelihood of severe hyperglycemia (HbA1c ≥8.0%). PhA/BFM profiling offers a novel approach to identify high-risk patients overlooked by conventional mass-based assessments.
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- p. EJ26-0238
Open AccessAssociation of phase angle versus skeletal muscle mass profiling with body fat mass in relation to glycemic control in type 2 diabetes: a cross-sectional study
While preserving skeletal muscle mass (SMM) is advocated in type 2 diabetes mellitus (T2DM), mass-based assessments often overlook muscle quality. This study aimed to investigate whether the balance between cellular integrity (phase angle [PhA]) and metabolic load (body fat mass [BFM]) is more clinically relevant to glycemic control than SMM-based profiling in patients with T2DM. In this cross-sectional study of 622 patients, participants were stratified into four groups based on sex-specific medians of PhA and BFM, and similarly for SMM and BFM. Multivariate logistic regression evaluated associations with glycemic targets (HbA1c <8.0% and <7.0%), adjusting for confounders. Sensitivity analyses utilized continuous Z-scores and interaction terms. High-PhA/High-BFM and High-PhA/Low-BFM groups showed significantly higher odds of HbA1c <8.0% compared with the Low-PhA/High-BFM reference group (adjusted odds ratio [OR] 2.05, 95% confidence interval [CI] 1.22–3.44; OR 2.10, 95% CI 1.21–3.64, respectively). Conversely, SMM/BFM combinations showed no significant associations. Neither profile was significantly associated with the stricter HbA1c <7.0% target. In continuous models, the PhA × BFM interaction was significantly associated with achievement of HbA1c <8.0% (p = 0.025), whereas SMM × BFM interaction was not. In conclusion, the PhA/BFM interplay shows a clearer association with glycemic control than SMM/BFM profiling in T2DM. Higher PhA may reflect a more favorable metabolic phenotype against adiposity and is associated with a lower likelihood of severe hyperglycemia (HbA1c ≥8.0%). PhA/BFM profiling offers a novel approach to identify high-risk patients overlooked by conventional mass-based assessments.
- Open Access
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73 (9) , EJ26-0061-1044
Indicators for predicting continuous insulin infusion therapy-related hypokalemia: multicenter retrospective cohort study
Hypokalemia is a common and potentially life-threatening complication of continuous intravenous insulin infusion (CII) in patients with hyperglycemic crises. However, no simple quantitative indicator can estimate the risk of hypokalemia at treatment initiation. This multicenter retrospective cohort study enrolled patients hospitalized for hyperglycemic crises who received CII. Clinical data available at CII initiation were collected. Machine-learning techniques were primarily employed for feature selection and model comparison to develop a simple, clinically interpretable prediction model. A logistic regression–based indicator was constructed using the most contributory variables and validated internally and externally. Hypokalemia was defined as a serum potassium level <3.5 mmol/L. The model-building and external validation cohorts included 99 and 55 patients, respectively. Among multiple candidate models, a lightweight logistic regression model using only two variables, serum potassium level and insulin infusion rate per body weight, was selected for clinical applicability. In internal validation, the model demonstrated good discriminative performance (receiver operating characteristic-area under the curve [ROC-AUC] 0.821). When applied to the external validation cohort, the ROC-AUC was 0.655, and accuracy decreased slightly. A lower threshold may increase sensitivity in screening, whereas a higher threshold may improve specificity. In conclusion, this study presents a simple and clinically applicable indicator for predicting CII-related hypokalemia using only two routinely available variables at treatment initiation. This model supports individualized electrolyte monitoring during the acute management of hyperglycemic crises. Additionally, it may facilitate safer and more efficient clinical decision-making without reliance on complex algorithms.
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73 (9) , EJ26-0061-1044
Open AccessIndicators for predicting continuous insulin infusion therapy-related hypokalemia: multicenter retrospective cohort study
Hypokalemia is a common and potentially life-threatening complication of continuous intravenous insulin infusion (CII) in patients with hyperglycemic crises. However, no simple quantitative indicator can estimate the risk of hypokalemia at treatment initiation. This multicenter retrospective cohort study enrolled patients hospitalized for hyperglycemic crises who received CII. Clinical data available at CII initiation were collected. Machine-learning techniques were primarily employed for feature selection and model comparison to develop a simple, clinically interpretable prediction model. A logistic regression–based indicator was constructed using the most contributory variables and validated internally and externally. Hypokalemia was defined as a serum potassium level <3.5 mmol/L. The model-building and external validation cohorts included 99 and 55 patients, respectively. Among multiple candidate models, a lightweight logistic regression model using only two variables, serum potassium level and insulin infusion rate per body weight, was selected for clinical applicability. In internal validation, the model demonstrated good discriminative performance (receiver operating characteristic-area under the curve [ROC-AUC] 0.821). When applied to the external validation cohort, the ROC-AUC was 0.655, and accuracy decreased slightly. A lower threshold may increase sensitivity in screening, whereas a higher threshold may improve specificity. In conclusion, this study presents a simple and clinically applicable indicator for predicting CII-related hypokalemia using only two routinely available variables at treatment initiation. This model supports individualized electrolyte monitoring during the acute management of hyperglycemic crises. Additionally, it may facilitate safer and more efficient clinical decision-making without reliance on complex algorithms.
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73 (8) , 993-1002
Overlap syndrome between sarcoidosis and Sjögren’s disease presenting as hypopituitarism: case report and review of literature
Sarcoidosis is a granulomatous disease that affects multiple organs; however, pituitary involvement is extremely rare. Although autoimmune diseases, such as Sjögren's disease (SjD), may coexist, overlapping cases presenting with hypopituitarism are exceedingly rare. A 76-year-old man was admitted with hyponatremia and altered consciousness as chief complaints. Endocrine testing revealed panhypopituitarism, and magnetic resonance imaging showed pituitary gland and pituitary stalk enlargement with homogeneous enhancement. Whole-body imaging revealed extensive lymphadenopathy. Histological examination of lymph node and lung biopsy specimens revealed non-necrotizing granulomas, indicative of sarcoidosis. Salivary gland biopsy and autoantibody testing confirmed the presence of concomitant SjD. Hormone replacement therapy markedly improved pituitary enlargement and pituitary hormone secretion, allowing the discontinuation of replacement therapy after 137 days. However, despite the improvement in pituitary and lymph node lesions, interstitial pneumonia subsequently developed due to SjD, necessitating systemic immunosuppressive therapy. In conclusion, this case demonstrates a rare overlap between sarcoidosis presenting with hypopituitarism and SjD, in which pituitary lesions improved, but immune activity progressed in other organs. Thus, immune-mediated disease activity may differ between organs in overlapping syndromes, and pituitary lesions in sarcoidosis do not necessarily parallel systemic disease activity.
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73 (8) , 993-1002
Overlap syndrome between sarcoidosis and Sjögren’s disease presenting as hypopituitarism: case report and review of literature
Sarcoidosis is a granulomatous disease that affects multiple organs; however, pituitary involvement is extremely rare. Although autoimmune diseases, such as Sjögren's disease (SjD), may coexist, overlapping cases presenting with hypopituitarism are exceedingly rare. A 76-year-old man was admitted with hyponatremia and altered consciousness as chief complaints. Endocrine testing revealed panhypopituitarism, and magnetic resonance imaging showed pituitary gland and pituitary stalk enlargement with homogeneous enhancement. Whole-body imaging revealed extensive lymphadenopathy. Histological examination of lymph node and lung biopsy specimens revealed non-necrotizing granulomas, indicative of sarcoidosis. Salivary gland biopsy and autoantibody testing confirmed the presence of concomitant SjD. Hormone replacement therapy markedly improved pituitary enlargement and pituitary hormone secretion, allowing the discontinuation of replacement therapy after 137 days. However, despite the improvement in pituitary and lymph node lesions, interstitial pneumonia subsequently developed due to SjD, necessitating systemic immunosuppressive therapy. In conclusion, this case demonstrates a rare overlap between sarcoidosis presenting with hypopituitarism and SjD, in which pituitary lesions improved, but immune activity progressed in other organs. Thus, immune-mediated disease activity may differ between organs in overlapping syndromes, and pituitary lesions in sarcoidosis do not necessarily parallel systemic disease activity.
- 25 November 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (2) , 1573-1577
Correlation between diabetes complications severity index and actual complication severity and diabetic medication in Japanese patients with type 2 diabetes mellitus
- 25 November 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (2) , 1573-1577
Correlation between diabetes complications severity index and actual complication severity and diabetic medication in Japanese patients with type 2 diabetes mellitus
- Open Access
- 28 July 2025
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 16 (10) , 1820-1828
A clinical model for highly accurate prediction of blood glucose depression after continuous intravenous insulin therapy in hyperglycemic emergencies, a multicenter retrospective cohort study
Background: Hyperglycemic emergencies are broadly classified into diabetic ketoacidosis and hyperosmotic hyperglycemic state. The purpose of this study was to develop a clinical model for predicting treatment of hyperglycemic emergencies. Methods: This study is a multicenter, retrospective cohort study. We used information on patients admitted to four medical institutions for treatment for hyperglycemic emergencies by diabetologists between April 1, 2010, and March 31, 2024, as the machine learning's training data. Multiple regression analysis was performed to find parameters that correlated with the difference between blood glucose levels before and after treatment initiation (ΔGlu), and a gradient boosting decision tree (GBDT) was created to predict ΔGlu. Results: Patients with type 1 diabetes ( n = 47) and type 2 diabetes ( n = 116) were included in the analysis of this study. We created a GBDT model using the following parameters as features: blood glucose level at the start of continuous intravenous insulin therapy, bicarbonate concentration, insulin flow rate, time elapsed since the start of continuous insulin therapy, and drip flow, which are important parameters for continuous intravenous insulin therapy for hyperglycemic emergencies. As a result, the correlation coefficient between predicted ΔGlu and actual ΔGlu was 0.83, showing a strong positive correlation. Conclusions: A GBDT model was developed to predict treatment after continuous intravenous insulin therapy using several variables during emergency care of patients with hyperglycemic emergencies. It is hoped that the application of this GBDT will allow appropriate provision of initial treatment, especially in nonspecialized medical facilities.
- 28 July 2025
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 16 (10) , 1820-1828
Open AccessA clinical model for highly accurate prediction of blood glucose depression after continuous intravenous insulin therapy in hyperglycemic emergencies, a multicenter retrospective cohort study
Background: Hyperglycemic emergencies are broadly classified into diabetic ketoacidosis and hyperosmotic hyperglycemic state. The purpose of this study was to develop a clinical model for predicting treatment of hyperglycemic emergencies. Methods: This study is a multicenter, retrospective cohort study. We used information on patients admitted to four medical institutions for treatment for hyperglycemic emergencies by diabetologists between April 1, 2010, and March 31, 2024, as the machine learning's training data. Multiple regression analysis was performed to find parameters that correlated with the difference between blood glucose levels before and after treatment initiation (ΔGlu), and a gradient boosting decision tree (GBDT) was created to predict ΔGlu. Results: Patients with type 1 diabetes ( n = 47) and type 2 diabetes ( n = 116) were included in the analysis of this study. We created a GBDT model using the following parameters as features: blood glucose level at the start of continuous intravenous insulin therapy, bicarbonate concentration, insulin flow rate, time elapsed since the start of continuous insulin therapy, and drip flow, which are important parameters for continuous intravenous insulin therapy for hyperglycemic emergencies. As a result, the correlation coefficient between predicted ΔGlu and actual ΔGlu was 0.83, showing a strong positive correlation. Conclusions: A GBDT model was developed to predict treatment after continuous intravenous insulin therapy using several variables during emergency care of patients with hyperglycemic emergencies. It is hoped that the application of this GBDT will allow appropriate provision of initial treatment, especially in nonspecialized medical facilities.
- 11 June 2025
- Published by Springer Nature in Diabetology International
- Vol. 16 (3) , 591-594
Rhabdomyolysis triggered by initiation of tirzepatide
We report a case of rhabdomyolysis triggered by initiation of tirzepatide, a novel dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The patient was a 68-year-old man with a medical history of type 2 diabetes mellitus (T2DM), dyslipidemia, and chronic kidney disease (CKD). After starting tirzepatide, he developed a significant elevation of creatine kinase (CK) and other muscle injury markers. These laboratory abnormalities rapidly returned to normal range after discontinuation of the drug. Based on the naranjo adverse drug reaction probability scale and the WHO-Uppsala Monitoring Centre (WHO-UMC) causality assessment system, the association between tirzepatide and rhabdomyolysis was classified as “probable.” To our knowledge, no previous cases of tirzepatide-induced rhabdomyolysis for T2DM have been reported in the literature. Although this adverse effect appears to be extremely rare, it is important to monitor CK levels when initiating tirzepatide therapy. Early detection of muscle injury markers may help prevent serious complications and ensure the safe use of this novel antidiabetic agent.
- 11 June 2025
- Published by Springer Nature in Diabetology International
- Vol. 16 (3) , 591-594
Rhabdomyolysis triggered by initiation of tirzepatide
We report a case of rhabdomyolysis triggered by initiation of tirzepatide, a novel dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The patient was a 68-year-old man with a medical history of type 2 diabetes mellitus (T2DM), dyslipidemia, and chronic kidney disease (CKD). After starting tirzepatide, he developed a significant elevation of creatine kinase (CK) and other muscle injury markers. These laboratory abnormalities rapidly returned to normal range after discontinuation of the drug. Based on the naranjo adverse drug reaction probability scale and the WHO-Uppsala Monitoring Centre (WHO-UMC) causality assessment system, the association between tirzepatide and rhabdomyolysis was classified as “probable.” To our knowledge, no previous cases of tirzepatide-induced rhabdomyolysis for T2DM have been reported in the literature. Although this adverse effect appears to be extremely rare, it is important to monitor CK levels when initiating tirzepatide therapy. Early detection of muscle injury markers may help prevent serious complications and ensure the safe use of this novel antidiabetic agent.
- Open Access
- 1 January 2025
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 72 (12) , 1369-1376
A case of Hailey–Hailey disease accompanied by Cushing’s syndrome and adrenal insufficiency due to long-term usage of topical steroids with review of literature
Hailey–Hailey disease (HHD), or familial benign chronic pemphigus, is a rare autosomal dominant disorder characterized by recurrent vesicles and erosions in intertriginous areas. Topical corticosteroids are the primary treatment, but their potential systemic side effects are often overlooked. Prolonged use on compromised skin can lead to excessive absorption, increasing the risk of iatrogenic Cushing’s syndrome and adrenal insufficiency. Here, we report the case of a 50-year-old woman with HHD who had been using topical clobetasol or betamethasone for over 10 years, reaching doses up to 50 g/day. She developed Cushingoid features, metabolic abnormalities, and suppression of the hypothalamic–pituitary–adrenal (HPA) axis. After tapering off topical corticosteroids, she developed adrenal insufficiency and associated withdrawal symptoms. Following the initiation of hydrocortisone replacement therapy, psychiatric symptoms, impaired glucose tolerance, and osteoporotic fractures emerged, suggesting exacerbation of iatrogenic Cushing’s syndrome. This case highlights the risk of systemic complications from chronic topical corticosteroid use, particularly in high-absorption areas. Gradual dose reduction, close endocrine monitoring, and individualized tapering strategies are essential to prevent severe outcomes. Clinicians should be aware of potential adrenal suppression and consider endocrine evaluation in patients receiving prolonged, high-dose topical corticosteroid therapy.
- 1 January 2025
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 72 (12) , 1369-1376
Open AccessA case of Hailey–Hailey disease accompanied by Cushing’s syndrome and adrenal insufficiency due to long-term usage of topical steroids with review of literature
Hailey–Hailey disease (HHD), or familial benign chronic pemphigus, is a rare autosomal dominant disorder characterized by recurrent vesicles and erosions in intertriginous areas. Topical corticosteroids are the primary treatment, but their potential systemic side effects are often overlooked. Prolonged use on compromised skin can lead to excessive absorption, increasing the risk of iatrogenic Cushing’s syndrome and adrenal insufficiency. Here, we report the case of a 50-year-old woman with HHD who had been using topical clobetasol or betamethasone for over 10 years, reaching doses up to 50 g/day. She developed Cushingoid features, metabolic abnormalities, and suppression of the hypothalamic–pituitary–adrenal (HPA) axis. After tapering off topical corticosteroids, she developed adrenal insufficiency and associated withdrawal symptoms. Following the initiation of hydrocortisone replacement therapy, psychiatric symptoms, impaired glucose tolerance, and osteoporotic fractures emerged, suggesting exacerbation of iatrogenic Cushing’s syndrome. This case highlights the risk of systemic complications from chronic topical corticosteroid use, particularly in high-absorption areas. Gradual dose reduction, close endocrine monitoring, and individualized tapering strategies are essential to prevent severe outcomes. Clinicians should be aware of potential adrenal suppression and consider endocrine evaluation in patients receiving prolonged, high-dose topical corticosteroid therapy.